VOBRAMITAMAB TAVATECAN
UNII 6CAR6LS9JU

Substance Identification & Data

This profile provides standardized clinical and technical data for Vobramitamab Tavatecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 6CAR6LS9JU.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3036552-56-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

6CAR6LS9JU

CAS Registry Number

3036552-56-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

VOBRAMITAMAB TAVATECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C206214

National Cancer Institute reference terminology for clinical and research data.

INN ID

13741

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Vobramitamab Tavatecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

VOBRAMITAMAB TAVATECAN

Common Names & Synonyms

IMMUNOGLOBULIN G1, ANTI-(HUMAN B7 HOMOLOG 3 PROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL PRCA157 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PRCA157 .KAPPA.-CHAIN, DIMER, 297,297'-BIS(N-(2-(ACETYLAMINO)-4-O-(2-(ACETYLAMINO)-6-AZIDO-2,6-DIDEOXY-.BETA.-D-GALACTOPYRANOSYL)-2-DEOXY-6-O-R-.BETA.-D-GLUCOPYRANOSYL)-L-ASPARAGINE), WHERE R = (H OR 6-DEOXY-.ALPHA.-L-GALACTOPYRANOSYL), CLICK REACTION PRODUCT WITH 1,1'-(((((13-(1.ALPHA.,8.ALPHA.,9.BETA.)-BICYCLO(6.1.0)NON-4-YN-9-YL-9,9-DIOXIDO-1,11-DIOXO-2,5,12-TRIOXA-9-THIA-8,10-DIAZATRIDEC-1-YL)AMINO)SULFONYL)IMINO)BIS(2,1-ETHANEDIYLOXYCARBONYL))BIS(L-VALYL-N-(4-((((((1S,9S)-9-ETHYL-5-FLUORO-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-4-METHYL-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)CARBONYL)OXY)METHYL)PHENYL)-L-ALANINAMIDE)

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD276 (B7H3, B7-H3, B7-RELATED PROTEIN 2, B7RP2, B7RP-2, B7 HOMOLOG 3, B7 HOMOLOGUE 3)), HUMANIZED MONOCLONAL ANTIBODY; CONJUGATED TO THE THE CAMPTOTHECIN DERIVATIVE EXATECAN VIA A LINKER (VOBRAMITAMAB TAVATECAN)

VOBRAMITAMAB TAVATECAN [INN]

External Clinical & Regulatory Resources

Previous UNII6CAK7AL29P

Next UNII6CAV9T8L8Q